N. Azli
Impact in
- Otorhinolaryngology top 0.5%
- Head and Neck Cancer Studies
- Oncology top 2%
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Neutropenia and Cancer Infections
Papers in
- Oncology 23
- Cancer Treatment and Pharmacology 16
- Viral-associated cancers and disorders 4
- Neutropenia and Cancer Infections 4
- Cancer Diagnosis and Treatment 2
-
- Head and Neck Cancer Studies 10
- Co-authors
- Esteban Cvitkovic (18 shared papers)A. Riva (10 shared papers)M. Bachouchi (11 shared papers)Véronique Dièras (7 shared papers)P. Fumoleau (10 shared papers)Jean‐Pierre Armand (7 shared papers)P. Wibault (6 shared papers)P Pouillart (5 shared papers)
In The Last Decade
N. Azli
35 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 75
- Otorhinolaryngology 480
- Oncology 1.0k
- Cancer Research 352
- Dermatology 185
- Pulmonary and Respiratory Medicine 159
Countries citing papers authored by N. Azli
This map shows the geographic impact of N. Azli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by N. Azli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites N. Azli more than expected).
Fields of papers citing papers by N. Azli
This network shows the impact of papers produced by N. Azli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by N. Azli. The network helps show where N. Azli may publish in the future.
Co-authors
The 25 scholars most cited alongside N. Azli, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 36 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2003 | 304 | |
| 2 | 1995 | 191 | |
| 3 | 1990 | 158 | |
| 4 | 2000 | 156 | |
| 5 | 1991 | 112 | |
| 6 | 1999 | 109 | |
| 7 | 1990 | 97 | |
| 8 | 2001 | 92 | |
| 9 | 1996 | 88 | |
| 10 | 1996 | 76 | |
| 11 | 1993 | 69 | |
| 12 | 1999 | 50 | |
| 13 | 1989 | 31 | |
| 14 | 2004 | 30 | |
| 15 | Docetaxel combined with vinorelbine: phase I results and new study designs. | 1997 | 23 |
| 16 | 1997 | 22 | |
| 17 | 2001 | 21 | |
| 18 | 1995 | 19 | |
| 19 | Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. | 2006 | 19 |
| 20 | 1990 | 19 |
About N. Azli
N. Azli is a scholar working on Oncology, Otorhinolaryngology, Pulmonary and Respiratory Medicine, Dermatology and Surgery, having authored 36 papers that have together received 1.8k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (16 papers), Head and Neck Cancer Studies (10 papers), Viral-associated cancers and disorders (4 papers), Chemotherapy-related skin toxicity (4 papers), Lung Cancer Treatments and Mutations (4 papers), Neutropenia and Cancer Infections (4 papers), Chemotherapy-induced cardiotoxicity and mitigation (2 papers) and Cancer Diagnosis and Treatment (2 papers). The work is most often cited by research in Otorhinolaryngology (480 citations), Oncology (1.0k citations), Cancer Research (352 citations), Dermatology (185 citations) and Pulmonary and Respiratory Medicine (159 citations). N. Azli has collaborated with scholars based in France, Belgium and Spain. Frequent co-authors include Esteban Cvitkovic, A. Riva, M. Bachouchi, Véronique Dièras, P. Fumoleau, Jean‐Pierre Armand, P. Wibault, P Pouillart, Pierre Kerbrat and B Chevallier. Their work appears in journals such as Journal of Clinical Oncology, European Journal of Cancer, Annals of Oncology, Cancer and Head & Neck.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.